| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urothelium | 4 | 2020 | 22 | 1.890 |
Why?
|
| Urologic Neoplasms | 3 | 2020 | 15 | 1.870 |
Why?
|
| Cytodiagnosis | 10 | 2022 | 44 | 1.730 |
Why?
|
| Biopsy, Fine-Needle | 10 | 2020 | 61 | 1.600 |
Why?
|
| Carcinoma | 6 | 2020 | 116 | 1.490 |
Why?
|
| Urine | 4 | 2021 | 38 | 1.470 |
Why?
|
| Thyroid Gland | 6 | 2018 | 79 | 1.310 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 461 | 1.100 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 584 | 1.050 |
Why?
|
| Pathology, Clinical | 3 | 2014 | 21 | 1.050 |
Why?
|
| Thyroid Neoplasms | 10 | 2021 | 71 | 1.010 |
Why?
|
| Nuclear Envelope | 4 | 2014 | 48 | 0.960 |
Why?
|
| Adenocarcinoma | 5 | 2020 | 323 | 0.950 |
Why?
|
| Thyroid Nodule | 3 | 2018 | 14 | 0.800 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 264 | 0.780 |
Why?
|
| DNA Mutational Analysis | 2 | 2020 | 188 | 0.780 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2020 | 135 | 0.750 |
Why?
|
| Neoplasms | 5 | 2014 | 1232 | 0.740 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 267 | 0.710 |
Why?
|
| Immunohistochemistry | 6 | 2020 | 851 | 0.710 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 24 | 0.710 |
Why?
|
| Colposcopy | 1 | 2020 | 20 | 0.690 |
Why?
|
| Cervix Uteri | 1 | 2020 | 56 | 0.680 |
Why?
|
| Kidney Pelvis | 1 | 2019 | 10 | 0.650 |
Why?
|
| Pathology, Molecular | 2 | 2016 | 10 | 0.640 |
Why?
|
| Ureter | 1 | 2019 | 24 | 0.640 |
Why?
|
| Thrombin | 1 | 2018 | 21 | 0.620 |
Why?
|
| Mediastinum | 1 | 2018 | 27 | 0.610 |
Why?
|
| Cytological Techniques | 2 | 2018 | 23 | 0.600 |
Why?
|
| Laboratories | 2 | 2016 | 27 | 0.580 |
Why?
|
| Microscopy | 2 | 2020 | 90 | 0.510 |
Why?
|
| Neoplasm Proteins | 2 | 2008 | 278 | 0.500 |
Why?
|
| Mutation | 6 | 2021 | 2458 | 0.490 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 651 | 0.480 |
Why?
|
| RNA-Binding Proteins | 2 | 2008 | 386 | 0.460 |
Why?
|
| Endoscopy | 2 | 2013 | 98 | 0.450 |
Why?
|
| Humans | 41 | 2022 | 59457 | 0.440 |
Why?
|
| Pathology, Surgical | 2 | 2013 | 12 | 0.430 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 95 | 0.430 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2013 | 147 | 0.420 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 29 | 0.420 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 226 | 0.350 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 1097 | 0.330 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2009 | 11 | 0.330 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2007 | 12 | 0.290 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2007 | 17 | 0.290 |
Why?
|
| Carcinoma, Papillary | 6 | 2015 | 35 | 0.280 |
Why?
|
| Endometrial Neoplasms | 1 | 2007 | 53 | 0.270 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2008 | 106 | 0.270 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 5129 | 0.260 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1560 | 0.240 |
Why?
|
| Interphase | 2 | 2013 | 68 | 0.240 |
Why?
|
| Female | 18 | 2021 | 30766 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 331 | 0.230 |
Why?
|
| Biopsy | 2 | 2019 | 410 | 0.230 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2021 | 71 | 0.230 |
Why?
|
| Middle Aged | 9 | 2020 | 16338 | 0.230 |
Why?
|
| Neoplasm Grading | 3 | 2020 | 79 | 0.230 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2004 | 4 | 0.220 |
Why?
|
| Fluorescent Dyes | 2 | 2018 | 196 | 0.220 |
Why?
|
| Models, Biological | 2 | 2010 | 1143 | 0.220 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 628 | 0.220 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2003 | 54 | 0.210 |
Why?
|
| Cell Nucleolus | 1 | 2004 | 68 | 0.210 |
Why?
|
| Indoles | 2 | 2015 | 106 | 0.210 |
Why?
|
| Aged | 9 | 2021 | 13427 | 0.200 |
Why?
|
| Adult | 8 | 2020 | 15697 | 0.200 |
Why?
|
| Sulfonamides | 2 | 2015 | 120 | 0.200 |
Why?
|
| Hematoxylin | 1 | 2022 | 11 | 0.200 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 12 | 0.200 |
Why?
|
| Endosonography | 1 | 2022 | 26 | 0.200 |
Why?
|
| Urinalysis | 2 | 2020 | 30 | 0.190 |
Why?
|
| Papillomavirus Infections | 2 | 2014 | 120 | 0.190 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2021 | 13 | 0.190 |
Why?
|
| Pericytes | 1 | 2021 | 15 | 0.190 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 30 | 0.190 |
Why?
|
| Quinolines | 1 | 2021 | 41 | 0.190 |
Why?
|
| Urinary Bladder | 1 | 2021 | 38 | 0.180 |
Why?
|
| Curettage | 1 | 2020 | 7 | 0.180 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 28 | 0.180 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2020 | 8 | 0.170 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 339 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2020 | 11 | 0.170 |
Why?
|
| Male | 11 | 2021 | 27784 | 0.170 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2021 | 51 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1028 | 0.160 |
Why?
|
| False Negative Reactions | 2 | 2016 | 40 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 474 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2011 | 193 | 0.150 |
Why?
|
| Plasma | 1 | 2018 | 35 | 0.150 |
Why?
|
| Retrospective Studies | 5 | 2019 | 6082 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 1 | 2018 | 394 | 0.140 |
Why?
|
| Papanicolaou Test | 2 | 2014 | 42 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2018 | 526 | 0.130 |
Why?
|
| Vaginal Smears | 2 | 2014 | 54 | 0.130 |
Why?
|
| Cell Nucleus | 5 | 2013 | 608 | 0.130 |
Why?
|
| Genes, p16 | 1 | 2015 | 6 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2019 | 815 | 0.130 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 20 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2341 | 0.130 |
Why?
|
| Gene Dosage | 1 | 2015 | 60 | 0.120 |
Why?
|
| Specimen Handling | 2 | 2013 | 61 | 0.120 |
Why?
|
| Laminin | 2 | 2014 | 74 | 0.120 |
Why?
|
| Algorithms | 2 | 2018 | 979 | 0.120 |
Why?
|
| Genes, erbB-2 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 179 | 0.110 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2014 | 1 | 0.110 |
Why?
|
| Prognosis | 3 | 2021 | 1597 | 0.110 |
Why?
|
| Diploidy | 1 | 2014 | 11 | 0.110 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 16 | 0.110 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2013 | 1 | 0.110 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2013 | 2 | 0.110 |
Why?
|
| United States | 3 | 2016 | 7432 | 0.110 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2013 | 28 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 154 | 0.110 |
Why?
|
| Goiter | 1 | 2013 | 9 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2013 | 53 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 140 | 0.100 |
Why?
|
| Thyroid Diseases | 1 | 2013 | 26 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 2014 | 98 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 121 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 372 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 196 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 94 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 299 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 237 | 0.090 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2010 | 2 | 0.090 |
Why?
|
| Pathology | 1 | 2011 | 11 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2011 | 69 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2013 | 458 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2013 | 338 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 2 | 2008 | 248 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 440 | 0.080 |
Why?
|
| Melanoma | 1 | 2014 | 318 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2014 | 1304 | 0.080 |
Why?
|
| Cell Polarity | 1 | 2010 | 110 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 720 | 0.080 |
Why?
|
| Chromatin | 2 | 2004 | 602 | 0.080 |
Why?
|
| Cytoplasm | 2 | 2008 | 271 | 0.080 |
Why?
|
| Cell Count | 1 | 2009 | 127 | 0.080 |
Why?
|
| Animals | 6 | 2015 | 19664 | 0.080 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 750 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 934 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 398 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 448 | 0.070 |
Why?
|
| Pancreatitis, Chronic | 1 | 2008 | 19 | 0.070 |
Why?
|
| Neoplasms, Ductal, Lobular, and Medullary | 1 | 2007 | 2 | 0.070 |
Why?
|
| Paraffin Embedding | 1 | 2007 | 16 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2014 | 1368 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2007 | 133 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2015 | 584 | 0.070 |
Why?
|
| Desmosomes | 1 | 2006 | 7 | 0.070 |
Why?
|
| Hemidesmosomes | 1 | 2006 | 6 | 0.070 |
Why?
|
| Basement Membrane | 1 | 2006 | 25 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2517 | 0.070 |
Why?
|
| Mammary Glands, Human | 1 | 2006 | 53 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 289 | 0.060 |
Why?
|
| Breast | 1 | 2007 | 174 | 0.060 |
Why?
|
| Heterografts | 2 | 2015 | 61 | 0.060 |
Why?
|
| Nuclear Matrix | 1 | 2004 | 28 | 0.060 |
Why?
|
| Gene Expression | 1 | 2007 | 810 | 0.060 |
Why?
|
| Phenotype | 2 | 2006 | 1138 | 0.060 |
Why?
|
| Selection, Genetic | 1 | 2004 | 71 | 0.060 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2003 | 3 | 0.050 |
Why?
|
| Microinjections | 1 | 2003 | 67 | 0.050 |
Why?
|
| Genes, ras | 1 | 2003 | 27 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2015 | 516 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2005 | 154 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 118 | 0.050 |
Why?
|
| Point Mutation | 1 | 2003 | 160 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2004 | 114 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2015 | 513 | 0.050 |
Why?
|
| Cell Division | 1 | 2004 | 443 | 0.050 |
Why?
|
| Risk | 2 | 2014 | 364 | 0.050 |
Why?
|
| Mitosis | 1 | 2003 | 209 | 0.050 |
Why?
|
| Ribosomes | 1 | 2004 | 154 | 0.050 |
Why?
|
| Transfection | 2 | 2015 | 675 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 186 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2004 | 1471 | 0.040 |
Why?
|
| Time Factors | 2 | 2004 | 3621 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2003 | 2095 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 1118 | 0.040 |
Why?
|
| Mice | 4 | 2015 | 10301 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 529 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 43 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 137 | 0.030 |
Why?
|
| Cytoskeleton | 2 | 2006 | 137 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 446 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 295 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 559 | 0.030 |
Why?
|
| Lamins | 1 | 2013 | 5 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 214 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 191 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2007 | 942 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2012 | 42 | 0.020 |
Why?
|
| DNA Damage | 1 | 2013 | 279 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 36 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 40 | 0.020 |
Why?
|
| Cell Line | 2 | 2006 | 1984 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 44 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2011 | 133 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1033 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 178 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 307 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2010 | 180 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 296 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 619 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 428 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2051 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 885 | 0.020 |
Why?
|
| Phyllodes Tumor | 1 | 2007 | 4 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 706 | 0.020 |
Why?
|
| Papilloma, Intraductal | 1 | 2007 | 5 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2007 | 85 | 0.020 |
Why?
|
| Carcinoma, Lobular | 1 | 2007 | 23 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2007 | 33 | 0.020 |
Why?
|
| Tight Junctions | 1 | 2006 | 20 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2377 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2006 | 133 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2005 | 51 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2006 | 84 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 132 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2004 | 7 | 0.010 |
Why?
|
| Paxillin | 1 | 2004 | 9 | 0.010 |
Why?
|
| Cell Death | 1 | 2006 | 271 | 0.010 |
Why?
|
| Focal Adhesions | 1 | 2004 | 23 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 31 | 0.010 |
Why?
|
| Cell Size | 1 | 2004 | 40 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2004 | 148 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 164 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2004 | 147 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2004 | 206 | 0.010 |
Why?
|
| Heterozygote | 1 | 2004 | 162 | 0.010 |
Why?
|
| Collagen | 1 | 2004 | 115 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4274 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 215 | 0.010 |
Why?
|
| PAX8 Transcription Factor | 1 | 2003 | 1 | 0.010 |
Why?
|
| Paired Box Transcription Factors | 1 | 2003 | 16 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 52 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2004 | 212 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2003 | 38 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 196 | 0.010 |
Why?
|
| Actins | 1 | 2004 | 259 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 656 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2004 | 188 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 289 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 805 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2004 | 253 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 142 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 428 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 300 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1555 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1469 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1553 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 1151 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2006 | 2901 | 0.010 |
Why?
|